Fig. 3: PRMT6 positively regulated the IL-6/STAT3 signaling pathway.
From: PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer
A GSEA analysis for GSE21653, patients grouped by the expression level of PRMT6. B Immunoblotting assays to detect the expression level of identified protein in cancer cells stably expressing Vector or PRMT6. C Immunoblotting assays to detect the expression level of STAT3 phosphorylation in cancer cells stably expressing Vector or PRMT6 with or without IL-6 (10 ng/mL) stimulation. D Immunoblotting assays to detect the expression level of identified protein in cancer cells stably expressing sgRNA-Control, sgRNA-PRMT6#1, or sgRNA-PRMT6#2. E Immunoblotting assays to detect the expression level of STAT3 phosphorylation in cancer cells stably expressing sgRNA-Control, sgRNA-PRMT6#1, or sgRNA-PRMT6#2 with or without IL-6 (10 ng/ml) stimulation. F and G RT-PCR assays to investigate the mRNA expression level of epithelial-mesenchymal transition markers in cancer cells stably expressing sgRNA-Control, sgRNA-PRMT6#1, or sgRNA-PRMT6#2; n = 6, P < 0.05. H Isolating cytoplasm and nucleus, immunoblotting assays to detect the expression level of STAT3 in cancer cells stably expressing sgRNA-Control or sgRNA-PRMT6#1. I After isolating the cytoplasm and nucleus, immunoblotting assays was performed to detect the expression level of STAT3 in cancer cells stably expressing Vector or PRMT6. J Immunofluorescence assays to assess the STAT3 cellular localization in cancer cells stably expressing sgRNA-Control or sgRNA-PRMT6#1 with or without IL-6 (10 ng/mL) stimulation. All immunoblotting assays were conducted three times, and the results were consistent.
